N Engl J Med 2014 Mar 27

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Related Questions

Should local consolidative therapy be offered to patients with oligometastatic NSCLC who do not progress after induction systemic therapy?

Radiation Oncology · University of Western Ontario Schulich School of Medicine & Dentistry

We were one of the three sites that accrued patients to this trial, and the benefits are compelling (a tripling of PFS, along with an OS benefit). Randomized phase II trials are usually not meant to be definitive, but these results are very informative for clinical practice. It's also important to n...